CTL inducing vaccines, Recombinant Adeno-associated Virus Vaccine (rAAV) and Modified Vaccinia Ankara (MVA) are being developed for
**Question:** CTL inducing vaccines, such as Recombinant Adeno-associated Virus Vaccine (rAAV) and Modified Vaccinia Ankara (MVA), are being developed for
A. Influenza
B. Hepatitis B
C. HIV
D. COVID-19
**Correct Answer:** .
**Core Concept:**
The question is about CTL (Cytotoxic T Lymphocyte)-inducing vaccines, which aim to stimulate the immune system to recognize and eliminate infected or malignant cells. Two types of vaccines are being discussed: rAAV (Recombinant Adeno-associated Virus Vaccine) and MVA (Modified Vaccinia Ankara). These vaccines primarily target cytotoxic T cells, which are part of the adaptive immune system responsible for recognizing and eliminating infected or abnormal cells.
**Why the Correct Answer is Right:**
Recombinant Adeno-associated Virus Vaccine (rAAV) and Modified Vaccinia Ankara (MVA) are being developed for vaccines due to their unique properties:
1. **rAAV:** This vaccine uses a harmless virus (adeno-associated virus) to deliver a foreign gene (antigen) into the host cells. This foreign gene then triggers an immune response, particularly CTLs, against the introduced antigen. rAAV is known for its safety and ability to efficiently deliver genes into target cells, making it a promising candidate for various infectious diseases and genetic therapies.
2. **MVA:** MVA is a modified form of the Vaccinia virus, a virus used in smallpox vaccine. By modifying the virus, its pathogenicity is reduced, making it safer for human use. MVA is designed to express antigens, which are recognized by the immune system, particularly CTLs, leading to an immune response against the expressed antigens.
**Why Each Wrong Option is Invalid:**
A. Influenza: While vaccines exist for influenza, rAAV and MVA are not specifically developed for this disease.
B. Hepatitis B: Hepatitis B vaccines are available, and rAAV and MVA are not designed for this particular virus.
C. HIV: There are no vaccines currently available for HIV, but rAAV and MVA are not specifically developed for this disease.
D. COVID-19: Although vaccines for COVID-19 exist, rAAV and MVA are not the primary platforms being developed for this pandemic disease.
**Why the Correct Answer is Right:**
rAAV and MVA are being investigated for their potential to target various diseases due to their capability to stimulate a strong immune response, particularly CTLs, against introduced antigens. These vaccines are being studied for their application in the fight against infectious diseases, genetic therapies, and cancer immunotherapies, among other fields. In contrast, the provided options (A, B, C, and D) represent specific diseases that already have available vaccines, and rAAV and MVA are not specifically designed or researched for these diseases.
**Clinical Applications:**
The development of rAAV and MVA for various diseases emphas